A few years later, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study, carried out in diabetic patients with a urinary albumin/creatinine ratio (UACR) > 300 mg/g, showed that canagliflozin reduced the UACR by 31% compared to placebo after 26 weeks of treatment [36]. Here, ALB is linked to diabetes mellitus.